Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 22.2% in January

Pharvaris N.V. (NASDAQ:PHVS) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 904,318 shares, a growth of 22.2% from the December 31st total of 739,825 shares. Based on an average daily volume of 240,394 shares, the days-to-cover ratio is presently 3.8 days. Based on an average daily volume of 240,394 shares, the days-to-cover ratio is presently 3.8 days.

Pharvaris Trading Down 4.0%

PHVS stock traded down $1.11 during trading on Wednesday, hitting $26.71. The company had a trading volume of 96,428 shares, compared to its average volume of 190,266. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80. The company has a 50 day simple moving average of $26.13 and a 200-day simple moving average of $23.95.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. On average, research analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several analyst reports. Morgan Stanley boosted their price objective on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Bank of America increased their price target on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, December 4th. Wedbush lifted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.56.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PHVS. General Atlantic L.P. lifted its stake in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC grew its position in shares of Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after buying an additional 368,000 shares during the last quarter. venBio Partners LLC raised its stake in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. lifted its position in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP boosted its stake in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.